Septicemia Due To Escherichia Coli — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for septicemia due to escherichia coli. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
2
Active US patents
72/100
Avg vulnerability
—
Annual revenue covered

Originators in Septicemia Due To Escherichia Coli

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Novartis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating septicemia due to escherichia coli. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
28
1
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tobi
tobramycin
 Novartis 2 72 — 2028-09-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8869794 Tobi method of use 75 2028-09-12
10207066 Tobi method of use 68 2030-11-04

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10207066 Tobi method of use 68 2030-11-04
8869794 Tobi method of use 75 2028-09-12

Related